What is Alpha Cognition Inc (ACOG)?

Alpha Cognition Inc (ACOG) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ACOG?

The current price of ACOG is $9.17. Prices are updated in real time on Stocks360.

What is ACOG's price-to-earnings (PE) ratio?

ACOG's trailing twelve-month PE ratio is -8.40, based on current price and earnings per share data available on Stocks360.

What is ACOG's market capitalization?

ACOG's market capitalization is $142,422,021.00, placing it in the small-cap tier.

Alpha Cognition Inc (ACOG)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$9.17

Market Cap

$142.42M

PE (TTM)

-8.40

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

2.23

Day Range

$8.67 – $9.20

52-wk Range

$4.50 – $10.14

Avg Volume

N/A

Volume

96.61K

Alpha Cognition Inc (ACOG) is a publicly traded company in the Healthcare sector. Latest price: $9.17. Market cap $142.42M. Trailing PE -8.40. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-28 · $6.60 2026-10-28 · $9.17 (+38.94%)

Earnings

Most Recent

Aug 13, 2026

EPS $-0.40 vs est. $-0.39

Missed by $0.01

Next Earnings

Nov 12, 2026

EPS estimate $-0.33

Proprietary Signals

Signal snapshot temporarily unavailable.

About Alpha Cognition Inc

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-8.40×
P/S (TTM)	9.33×
P/B	3.77×
P/FCF (TTM)	-4.56×
EV / EBITDA	-3.68×
EV / Sales	6.62×
Earnings Yield	-11.74%
Free Cash Flow Yield	-21.92%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$101.04M
Revenue (TTM)	$15.26M
Net Income (TTM)	-$16.72M
Free Cash Flow (TTM)	-$31.22M
Net Debt	-$41.38M
Working Capital	$51.51M
Gross Margin	89.89%
Operating Margin	-190.55%
Net Margin	-153.61%
Return on Equity	-45.33%
Return on Invested Capital	-50.04%